Jacobo Mintzer to Double-Blind Method
This is a "connection" page, showing publications Jacobo Mintzer has written about Double-Blind Method.
Connection Strength
0.915
-
Effect of methylphenidate on attention in apathetic AD patients in a randomized, placebo-controlled trial. Int Psychogeriatr. 2014 Feb; 26(2):239-46.
Score: 0.086
-
Aripiprazole for the treatment of psychoses in institutionalized patients with Alzheimer dementia: a multicenter, randomized, double-blind, placebo-controlled assessment of three fixed doses. Am J Geriatr Psychiatry. 2007 Nov; 15(11):918-31.
Score: 0.056
-
Risperidone in the treatment of psychosis of Alzheimer disease: results from a prospective clinical trial. Am J Geriatr Psychiatry. 2006 Mar; 14(3):280-91.
Score: 0.050
-
The efficacy of galantamine in the treatment of Alzheimer's disease: comparison of patients previously treated with acetylcholinesterase inhibitors to patients with no prior exposure. Int J Geriatr Psychiatry. 2003 Apr; 18(4):292-7.
Score: 0.041
-
Olanzapine in the treatment of anxiety symptoms due to Alzheimer's disease: a post hoc analysis. Int J Geriatr Psychiatry. 2001 Dec; 16 Suppl 1:S71-7.
Score: 0.037
-
Rivastigmine Transdermal Patch Treatment for Moderate to Severe Cognitive Impairment in Veterans with Traumatic Brain Injury (RiVET Study): A Randomized Clinical Trial. J Neurotrauma. 2021 07 15; 38(14):1943-1952.
Score: 0.036
-
Escitalopram for agitation in Alzheimer's disease (S-CitAD): Methods and design of an investigator-initiated, randomized, controlled, multicenter clinical trial. Alzheimers Dement. 2019 11; 15(11):1427-1436.
Score: 0.032
-
Heterogeneity of Treatment Response to Citalopram for Patients With Alzheimer's Disease With Aggression or Agitation: The CitAD Randomized Clinical Trial. Am J Psychiatry. 2016 May 01; 173(5):465-72.
Score: 0.025
-
Sedation mediates part of Citalopram's effect on agitation in Alzheimer's disease. J Psychiatr Res. 2016 Mar; 74:17-21.
Score: 0.025
-
A randomized, double-blind, placebo-controlled trial of resveratrol for Alzheimer disease. Neurology. 2015 Oct 20; 85(16):1383-91.
Score: 0.024
-
Effect of Dextromethorphan-Quinidine on Agitation in Patients With Alzheimer Disease Dementia: A Randomized Clinical Trial. JAMA. 2015 Sep 22-29; 314(12):1242-54.
Score: 0.024
-
Change in agitation in Alzheimer's disease in the placebo arm of a nine-week controlled trial. Int Psychogeriatr. 2015 Dec; 27(12):2059-67.
Score: 0.024
-
Citalopram for the Treatment of Agitation in Alzheimer Dementia: Genetic Influences. J Geriatr Psychiatry Neurol. 2016 Mar; 29(2):59-64.
Score: 0.024
-
Time to Response to Citalopram Treatment for Agitation in Alzheimer Disease. Am J Geriatr Psychiatry. 2015 Nov; 23(11):1127-33.
Score: 0.024
-
Changes in QTc interval in the citalopram for agitation in Alzheimer's disease (CitAD) randomized trial. PLoS One. 2014; 9(6):e98426.
Score: 0.022
-
Effect of citalopram on agitation in Alzheimer disease: the CitAD randomized clinical trial. JAMA. 2014 Feb 19; 311(7):682-91.
Score: 0.022
-
Is sertraline treatment or depression remission in depressed Alzheimer patients associated with improved caregiver well being? Depression in Alzheimer's Disease Study 2. Am J Geriatr Psychiatry. 2014 Jan; 22(1):14-24.
Score: 0.022
-
Effect of vitamin E and memantine on functional decline in Alzheimer disease: the TEAM-AD VA cooperative randomized trial. JAMA. 2014 Jan 01; 311(1):33-44.
Score: 0.022
-
Safety and efficacy of methylphenidate for apathy in Alzheimer's disease: a randomized, placebo-controlled trial. J Clin Psychiatry. 2013 Aug; 74(8):810-6.
Score: 0.021
-
Vitamin E and memantine in Alzheimer's disease: clinical trial methods and baseline data. Alzheimers Dement. 2014 Jan; 10(1):36-44.
Score: 0.021
-
Designing a trial to evaluate potential treatments for apathy in dementia: the apathy in dementia methylphenidate trial (ADMET). Am J Geriatr Psychiatry. 2013 Jun; 21(6):549-59.
Score: 0.020
-
Cognitive outcomes after sertaline treatment in patients with depression of Alzheimer disease. Am J Geriatr Psychiatry. 2012 Dec; 20(12):1036-44.
Score: 0.020
-
Relapse risk after discontinuation of risperidone in Alzheimer's disease. N Engl J Med. 2012 Oct 18; 367(16):1497-507.
Score: 0.020
-
Subgroup analysis of US and non-US patients in a global study of high-dose donepezil (23 mg) in moderate and severe Alzheimer's disease. Am J Alzheimers Dis Other Demen. 2012 Sep; 27(6):421-32.
Score: 0.020
-
The antipsychotic discontinuation in Alzheimer disease trial: clinical rationale and study design. Am J Geriatr Psychiatry. 2012 Apr; 20(4):362-73.
Score: 0.019
-
Citalopram for agitation in Alzheimer's disease: design and methods. Alzheimers Dement. 2012; 8(2):121-30.
Score: 0.019
-
Sertraline for the treatment of depression in Alzheimer disease. Am J Geriatr Psychiatry. 2010 Feb; 18(2):136-45.
Score: 0.017
-
Memantine treatment in patients with mild to moderate Alzheimer's disease already receiving a cholinesterase inhibitor: a randomized, double-blind, placebo-controlled trial. Curr Alzheimer Res. 2008 Feb; 5(1):83-9.
Score: 0.014
-
The efficacy and safety of risperidone in the treatment of psychosis of Alzheimer's disease and mixed dementia: a meta-analysis of 4 placebo-controlled clinical trials. Int J Geriatr Psychiatry. 2007 May; 22(5):475-84.
Score: 0.014
-
Quetiapine to treat agitation in dementia: a randomized, double-blind, placebo-controlled study. Curr Alzheimer Res. 2007 Feb; 4(1):81-93.
Score: 0.013
-
Quetiapine treatment of psychosis associated with dementia: a double-blind, randomized, placebo-controlled clinical trial. Am J Geriatr Psychiatry. 2006 Sep; 14(9):767-76.
Score: 0.013
-
Divalproex sodium in nursing home residents with possible or probable Alzheimer Disease complicated by agitation: a randomized, controlled trial. Am J Geriatr Psychiatry. 2005 Nov; 13(11):942-9.
Score: 0.012
-
A randomized, placebo-controlled study of the efficacy and safety of sertraline in the treatment of the behavioral manifestations of Alzheimer's disease in outpatients treated with donepezil. Int J Geriatr Psychiatry. 2004 Jan; 19(1):9-18.
Score: 0.011
-
Randomized, placebo-controlled trial of the effects of donepezil on neuronal markers and hippocampal volumes in Alzheimer's disease. Am J Psychiatry. 2003 Nov; 160(11):2003-11.
Score: 0.011
-
Donepezil in vascular dementia: a randomized, placebo-controlled study. Neurology. 2003 Aug 26; 61(4):479-86.
Score: 0.011
-
Comparison of rapidly acting intramuscular olanzapine, lorazepam, and placebo: a double-blind, randomized study in acutely agitated patients with dementia. Neuropsychopharmacology. 2002 Apr; 26(4):494-504.
Score: 0.010
-
Effects of a flexible galantamine dose in Alzheimer's disease: a randomised, controlled trial. J Neurol Neurosurg Psychiatry. 2001 Nov; 71(5):589-95.
Score: 0.009
-
A double-blind placebo-controlled case study of the use of donepezil to improve cognition in a schizoaffective disorder patient: functional MRI correlates. Neurocase. 2001; 7(2):105-10.
Score: 0.009
-
A 24-week randomized trial of controlled-release physostigmine in patients with Alzheimer's disease. Neurology. 1999 Apr 12; 52(6):1146-52.
Score: 0.008
-
Comparison of risperidone and placebo for psychosis and behavioral disturbances associated with dementia: a randomized, double-blind trial. Risperidone Study Group. J Clin Psychiatry. 1999 Feb; 60(2):107-15.
Score: 0.008